<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451812</url>
  </required_header>
  <id_info>
    <org_study_id>105-6435C</org_study_id>
    <secondary_id>104-4855A</secondary_id>
    <nct_id>NCT03451812</nct_id>
  </id_info>
  <brief_title>Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer</brief_title>
  <acronym>PCAPETMR</acronym>
  <official_title>Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To correlate the blood/urine metabolomic biomarkers with PET/MR imaging.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To evaluate the sensitivity and specificity of the PET/MR in diagnosis of prostate&#xD;
           cancer.&#xD;
&#xD;
        2. To examine the diagnostic performance among subgroups of defined high-risk and low-risk&#xD;
           subjects.&#xD;
&#xD;
        3. To interrogate the metabolomic alterations with the molecular PET/MR to develop workable&#xD;
           panel biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to 2015 National Comprehensive Cancer Network (NCCN) guideline, medical imaging&#xD;
      plays important roles for detection and staging for PCa, in addition to blood or urine&#xD;
      biomarkers. Although there are a number of very different diagnostic imaging methods, e.g.&#xD;
      transrectal ultrasound (TRUS), computed tomography (CT), magnetic resonance (MR) imaging and&#xD;
      spectroscopy, or 18F-FDG positron emission tomography (PET), none of these have gained a&#xD;
      dominant role as the optimum method for all clinical scenarios.The recently added&#xD;
      armamentarium, PET/MR, might improve diagnosis in this regard.&#xD;
&#xD;
      Therefore, we conduct this trial to identify the ability of [11C]Choline PET/MR to evaluate&#xD;
      the patients with prostate cancer, especially under the circumstance of elevated PSA level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy</measure>
    <time_frame>1 year</time_frame>
    <description>sensitivity, specificity, accuracy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>prostate cancer</arm_group_label>
    <description>The newly diagnostic number for the high-risk PCa patients in our hospital annually is ~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in a tertiary referral center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  40-85 years of age&#xD;
&#xD;
          -  Patients with a biopsy-proven or clinically highly suspected prostate adenocarcinoma,&#xD;
             or benign prostatic hyperplasia&#xD;
&#xD;
          -  Able to tolerate [11C]Choline PET scan and MRI scan&#xD;
&#xD;
          -  Written informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute prostatitis or non-urologic bacterial infection requiring medical treatment&#xD;
             within the last 3 months.&#xD;
&#xD;
          -  History of AIDS in the period prior to the screening.3&#xD;
&#xD;
          -  Contraindications to [11C]Choline PET/MR scans&#xD;
&#xD;
               1. Surgical implants including pacemaker implants, cochlear implants, dentures held&#xD;
                  in place by magnets imbedded in the gums and aneurysm clips except those inserted&#xD;
                  at CGMH&#xD;
&#xD;
               2. Metallic prosthesis of the hip or pelvic region&#xD;
&#xD;
               3. Renal function impairment with estimated glomerular filtration rate (eGFR) &lt; 30&#xD;
                  ml/min/1.73 m2&#xD;
&#xD;
               4. Claustrophobia&#xD;
&#xD;
               5. Medical drugs with choline&#xD;
&#xD;
               6. Previous allergy to carbon-labeled radionuclide&#xD;
&#xD;
          -  Active other malignancy within the last 2 years&#xD;
&#xD;
          -  Subject which in the opinion of the investigator preclude participation for scientific&#xD;
             reasons, for reasons of compliance, or for reasons of the subject's safety.&#xD;
&#xD;
          -  Prisoners or patients with mental illness&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gigin Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Imaging and Intervention, Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gigin Lin, MD, PhD</last_name>
    <phone>886-3281200</phone>
    <phone_ext>2575</phone_ext>
    <email>giginlin@cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital</name>
      <address>
        <city>Guishan</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gigin Lin, MD, PhD</last_name>
      <phone>886-3281200</phone>
      <phone_ext>2575</phone_ext>
      <email>giginlin@cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Gigin Lin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>metabolomics</keyword>
  <keyword>molecular imaging</keyword>
  <keyword>PET</keyword>
  <keyword>MRI</keyword>
  <keyword>11C-choline tracer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

